Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

Change From Baseline of Amyloid Beta (Aβ) 1-38 , Aβ 1-40 and Aβ 1-42 Cerebrospinal Fluid (CSF) Concentrations

CSF samples were collected by lumbar puncture for assessment.

Time frame: Day 92

Summary of Plasma PK Parameter: Cmax

Cmax = the observed maximum plasma concentration following drug administration. Blood samples were collected to assess Cmax. The PK analysis set was used for the analysis.

Time frame: Days 1, 91

Summary of Plasma PK Parameter: AUCtau

AUCtau = the area under the plasma concentration-time curve from zero to the end of the dosing interval tau. Blood samples were collected to assess AUCtau.

Time frame: Days 1 and 91

Summary of Plasma PK Parameter: Tmax

Tmax = the time to reach the maximum concentration after drug administration. Blood samples were collected to assess Tmax.

Time frame: Days 1 and 91

Summary of Plasma PK Parameter: Tlag

Tlag = time delay between drug administration and first observed concentration above the lower limit of quantification (LOQ) in plasma . Blood samples were collected to assess Tlag.

Time frame: Days 1 and 91

Summary of Plasma PK Parameter: T1/2

T1/2 = the terminal elimination half-life. Blood samples were collected to assess T/12.